E-DRUG: Therapeutics Letter #58: Benign Prostatic Hypertrophy
---------------------------------------------------
I would like to bring to your attention the March 2006 issue (#58) of the Therapeutics Letter: "Benign Prostatic Hypertrophy: An update on drug therapy" that has just been published on the Therapeutics Initiative web site at http://www.ti.ubc.ca/pages/letter58.htm
In this Therapeutics Letter we summarize the currently available evidence of benefit and harm from alpha blockers and 5-α-reductase inhibitors in the treatment of benign prostatic hypertrophy (BPH).
I invite you to drop by and have a look at this Letter. Please feel free to forward this message to any of your friends or colleagues that might be interested in this topic.
We would appreciate receiving your comments on this Therapeutics Letter and its possible implications in clinical practice.
Best regards,
Ciprian Jauca
Manager
Therapeutics Initiative
University of British Columbia
Department of Anesthesiology, Pharmacology & Therapeutics
2176 Health Sciences Mall
Vancouver, BC V6T 1Z3
Canada
Email: jauca@ti.ubc.ca
Tel: +1 (604) 822-0700
Fax: +1 (604) 822-0701
Web: www.ti.ubc.ca